Eli Lilly pays up to $3.8 billion for psychedelic therapy biotech

WHAT HAPPENED

Eli Lilly closed the acquisition of AtaiBeckley for $2.8 billion in cash and could pay up to an additional $1 billion if its psychedelic treatments for depression meet goals and obtain approvals.

WHY IT MATTERS

Lilly aims to enter mental health, where millions suffer from depression that does not improve with common antidepressants. If the drugs work and are authorized, they could open new revenue streams; meanwhile, construction, pharmaceutical production, and biotechnology continue to lack that boost.

AND FOR YOUR PORTFOLIO

For those holding Lilly shares, this is a multi-year bet, not an immediate source of income: the treatments are still being tested and may not be approved. The acquisition also shows that large pharmaceutical companies continue to seek small biotechs with promising drugs.